Ductal intraepithelial neoplasia: Postsurgical outcome for 1,267 women cared for in one single institution over 10 years

Oncologist

Volumn 14, Issue 3, 2009, Pages 201-212

  Guerrieri Gonzaga, Aliana ^a   Botteri, Edoardo ^a   Rotmensz, Nicole ^a   Bassi, Fabio ^a   Lntra, Mattia ^a   Serrano, Davide ^a   Renne, Giuseppe ^a   Luini, Alberto ^a   Cazzaniga, Massimiliano ^a   Goldhirsch, Aaron ^a   Colleoni, Marco ^a   Viale, Giuseppe ^a,c   Ivaldi, Giovanni ^a   Bagnardi, Vincenzo ^a,b   Lazzeroni, Matteo ^a,d   Decensi, Andrea ^a,e   Veronesi, Umberto ^a   Bonanni, Bernardo ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

^e GALLIERA HOSPITAL   (Italy)

Author keywords

Chemoprevention; Intraepithelial neoplasia; Radiotherapy; Tamoxifen

Indexed keywords

ANASTROZOLE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FENRETINIDE; TAMOXIFEN;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER RECURRENCE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; HAZARD RATIO; HISTOPATHOLOGY; HUMAN; INTRADUCTAL CARCINOMA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MASTECTOMY; OUTCOME ASSESSMENT; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; RISK BENEFIT ANALYSIS; RISK FACTOR; SURGICAL TECHNIQUE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; COHORT STUDIES; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; RISK FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 63849240522     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2008-0203     Document Type: Article

References (43)

1. Veronesi U, Viale G, Rotmensz N et al. Rethinking TNM: Breast cancer TNM classification for treatment decision-making and research. Breast 2006;15:3-8.
2. Ernster VL, Ballard-Barbash R, Barlow WE et al. Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst 2002;94:1546-1554.
3. Fisher B, Dignam J, Wolmark N et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 1998;16:441-452.
4. Julien JP, Bijker N, Fentiman IS et al. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: First results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Lancet 2000;355:528 -533.
5. Houghton J, George WD, Cuzick J et al. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: Randomised controlled trial. Lancet 2003;362:95-102.
6. Emdin SO, Granstrand B, Ringberg A et al. SweDCIS: Radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results ofa randomised trial in a population offered mammography screening. Acta Oncol 2006;45:536 -543.
7. Fisher B, Land S, Mamounas E et al. Prevention of invasive breast cancer in women with ductal carcinoma in situ: An update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol 2001;28: 400 -418.
8. Bijker N, Meijnen P, Peterse JL et al. Breast-conserving treatment with or with out radiotherapy in ductal carcinoma-in-situ: Ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853-a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 2006;24:3381-3387.
9. Viani GA, Stefano EJ, Afonso SL et al. Breast-conserving surgery with or without radiotherapy in women with ductal carcinoma in situ: A metaanalysis of randomized trials. Radiat Oncol 2007;2:28.
10. FisherB, Dignam J, Wolmark N et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999;353:1993-2000.
11. Decensi A, Gandini S, Serrano D et al. Randomized dose-ranging trial of tamoxifen at low doses in hormone replacement therapy users. J Clin Oncol 2007;25:4201-4209.
12. Guerrieri-Gonzaga A, Robertson C, Bonanni B et al. Preliminary results on safety and activity of a randomized, double-blind, 2 × 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in premenopausal women. J Clin Oncol 2006;24:129-135.
13. Decensi A, Robertson C, Viale G et al. A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. J Natl Cancer Inst 2003;95:779-790.
14. Marubini E. Analysing Survival Data From Clinical Trials and Observational Studies. Chichester, UK: John Wiley & Sons, 1995:1-361.
15. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988;16:1141-1154.
16. Putter H, Fiocco M, Geskus R. Tutorial in biostatistics: Competing risks and multi-state models. Stat Med 2007;26:2389-2430.
17. Burstein HJ, Polyak K, Wong JS et al. Ductal carcinoma in situ of the breast. N Engl J Med 2004;350:1430-1441.
18. Leonard GD, Swain SM. Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst 2004;96:906-920.
19. Patani N, Cutuli B, Mokbel K. Current management of DCIS: A review. Breast Cancer Res Treat 2008;111:1-10.
20. Boughey JC, Gonzalez RJ, Bonner E et al. Current treatment and clinical trial developments for ductal carcinoma in situ of the breast. The Oncologist 2007;12:1276-1287.
21. Boyages J, Delaney G, Taylor R. Predictors of local recurrence after treatment of ductal carcinoma in situ: A meta-analysis. Cancer 1999;85:616-628.
22. American College of Radiology. Practice guideline for the management of ductal carcinoma in-situ of the breast (DCIS). J Am Coll Surg 2007;205: 145-161.
23. Curado MP, Edwards B, Shin HR et al., eds. Cancer Incidence in Five Continents, Volume IX. IARC Scientific Publications No. 160. Lyon, France:IARC, 2007.
24. Cutuli B, Cohen-Solal-le Nir C, de Lafontan B et al. Breast-conserving therapy for ductal carcinoma in situ of the breast: The French Cancer Centers' experience. Int J Radiat Oncol Biol Phys 2002;53:868-879.
25. Schouten van der Velden AP, van Vugt R, Van Dijck JA et al. Local recurrences after different treatment strategies for ductal carcinoma in situ of the breast: A population-based study in the East Netherlands. Int J Radiat On col Biol Phys 2007;69:703-710.
26. Sumner WE 3rd, Koniaris LG, Snell SE et al. Results of 23,810 cases of ductal carcinoma-in-situ. Ann Surg Oncol 2007;14:1638-1643.
27. Meijnen P, Oldenburg HS, Peterse JL et al. Clinical outcome after selective treatment of patients diagnosed with ductal carcinoma in situ ofthe breast. Ann Surg On col 2008;15:235-243.
28. Kirova YM, Gambotti L, De Rycke Y et al. Risk of second malignancies after adjuvant radiotherapy for breast cancer: A large-scale, single-institution review. Int J Radiat Oncol Biol Phys 2007;68:359-363.
29. Nuyten DS, Kreike B, Hart AA et al. Predicting a local recurrence after breast-conserving therapy by gene expression profiling. Breast Cancer Res 2006;8:R62.
30. Barnes NL, Khavari S, Boland GP et al. Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast. Clin Cancer Res 2005;11:2163-2168.
31. Baum M, Budzar AU, Cuzick J et al.; ATAC Trialists Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet2002;359:2131-2139.
32. Gibson LJ, Dawson CK, Lawrence DH et al. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst Rev 2007;(1):CD003370.
33. Cuzick J. Aromatase inhibitors in prevention-data from the ATAC(Arimi-dex, Tamoxifen Alone or in Combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study). Recent Results CancerRes 2003;163:96-103; discussion 264-266.
34. Baum M, Buzdar A, Cuzick J et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of the ATAC (Arimi-dex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer2003;98:1802-1810.
35. Buckley MM, Goa KL. Tamoxifen: A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use. Drugs 1989;37:451-490.
36. Collins LC, Schnitt SJ. HER2 protein overexpression in estrogen receptor-positive ductal carcinoma in situ of the breast: Frequency and implications for tamoxifen therapy. Mod Pathol 2005;18:615-620.
37. Osborne CK, Bardou V, Hopp TA et al. Role of the estrogen receptor co-activator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 2003;95:353-361.
38. De Placido S, De Laurentiis M, Carlomagno C et al. Twenty-year results of the Naples GUN randomized trial: Predictive factors of adjuvant tamoxifen efficacy in early breast cancer. Clin Cancer Res 2003;9:1039-1046.
39. Gonzalez RJ, Buzdar AU, Fraser Symmans W et al. Novel clinical trial designs for treatment of ductal carcinoma in situ of the breast with trastu-zumab (Herceptin). BreastJ 2007;13:72-75.
40. Aubele M, Mattis A, Zitzelsberger H et al. Extensive ductal carcinoma in situ with small foci of invasive ductal carcinoma: Evidence of genetic resemblance by CGH. Int J Cancer 2000;85:82-86.
41. Götte M, Kersting C, Radke I et al. An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ. Breast Cancer Res 2007;9:R8.
42. Hannemann J, Velds A, Halfwerk JB et al. Classification of ductal carcinoma in situ by gene expression profiling. Breast Cancer Res 2006;8:R61.
43. Partridge A, Adloff K, Blood E et al. Risk perceptions and psychosocial outcomes of women with ductal carcinoma in situ: Longitudinal results from a cohort study. J Natl CancerInst2008;100:243-251.